Published in Urol Oncol on February 28, 2016
Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT00861614
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT01057810
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | NCT01968109
Neoadjuvant Ipilimumab in Prostate Cancer | NCT01194271
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma | NCT01524991
Safety Study of MGA271 in Refractory Cancer | NCT01391143
IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC) | NCT00351949
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med (2017) 0.91
Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases. J Thorac Dis (2016) 0.78
A Nonselective Cyclooxygenase Inhibitor Enhances the Activity of Vinblastine in a Naturally-Occurring Canine Model of Invasive Urothelial Carcinoma. Bladder Cancer (2016) 0.75
Jagged1 upregulation in prostate epithelial cells promotes formation of reactive stroma in the Pten null mouse model for prostate cancer. Oncogene (2016) 0.75
Salvage Therapy Options for Local Prostate Cancer Recurrence After Primary Radiotherapy: a Literature Review. Curr Urol Rep (2017) 0.75
Pan-urologic cancer genomic subtypes that transcend tissue of origin. Nat Commun (2017) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 14.90
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 12.36
CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 9.80
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J (1992) 8.86
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol (2004) 7.16
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med (2006) 7.10
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol (1996) 6.79
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature (2002) 6.58
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 6.17
The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol (1993) 5.65
Mechanisms of immune evasion by tumors. Adv Immunol (2006) 5.34
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med (2010) 4.79
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med (2009) 4.68
Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res (2005) 4.23
B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol (2001) 4.10
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81
Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science (2007) 3.70
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother (2009) 3.62
B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity (2003) 3.47
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (2007) 3.32
Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res (1999) 3.29
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res (2007) 3.23
B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity (2003) 3.18
The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol (2003) 3.18
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A (2001) 3.15
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med (2005) 3.13
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A (2010) 3.12
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res (2008) 3.09
Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res (2000) 2.89
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol (2014) 2.78
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res (2013) 2.76
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71
B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A (2003) 2.66
Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med (2003) 2.65
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol (2013) 2.64
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A (1997) 2.53
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol (2013) 2.35
Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J Immunol (2005) 2.34
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res (2009) 2.32
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A (2006) 2.24
B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res (2007) 2.19
Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate (2009) 2.17
History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol (2007) 2.15
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res (2011) 1.97
Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res (2008) 1.97
Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One (2012) 1.77
Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A (1999) 1.61
LAG-3 in Cancer Immunotherapy. Curr Top Microbiol Immunol (2011) 1.58
T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res (2008) 1.58
Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res (2009) 1.51
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods (2009) 1.48
PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene (2008) 1.41
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res (2013) 1.39
Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol (2006) 1.36
Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology (2013) 1.35
Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res (2008) 1.21
CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol (1995) 1.16
B7-h3 and its role in antitumor immunity. Clin Dev Immunol (2010) 1.14
A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res (2009) 1.12
Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses. Cancer Res (2013) 1.11
Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol (2012) 1.09
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur J Cancer (2009) 1.09
High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol (2007) 1.08
Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes. Eur J Immunol (1994) 1.06
Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res (2012) 1.06
Pox viral vaccine approaches. Semin Oncol (2005) 0.98
Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. Clin Cancer Res (2009) 0.96
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med (2013) 0.93
Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer. Int J Radiat Oncol Biol Phys (2010) 0.92
The role of interferon and interleukin-2 in the immunotherapeutic approach to renal cell carcinoma. Semin Oncol (1991) 0.89
Sipuleucel-T for the treatment of advanced prostate cancer. Semin Oncol (2012) 0.86
Prognostic value of T cell immunoglobulin mucin-3 in prostate cancer. Asian Pac J Cancer Prev (2013) 0.84
Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population? Int J Urol (2012) 0.81
Dendritic and lymphocytic cell infiltration in prostate carcinoma. Histol Histopathol (2013) 0.80